---
layout: post
title: "Revocation of Two Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of Ebola; Availability"
date: 2026-02-05 18:55:17 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-08281
original_published: 2023-04-20 00:00:00 +0000
significance: 8.00
---

# Revocation of Two Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of Ebola; Availability

**Published:** February 05, 2026 18:55 UTC
**Source:** Federal Register
**Original Published:** April 20, 2023 00:00 UTC
**Document Number:** 2023-08281

## Summary

The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorizations (EUAs) (the Authorizations) issued to BioFire Defense, LLC, for the FilmArray NGDS BT-E Assay, and Biocartis NV, for the Idylla Rapid Ebola Virus Triage Test. FDA revoked these Authorizations under the Federal Food, Drug, and Cosmetic Act (FD&C Act) as requested by each Authorization holder. The revocations, which include an explanation of the reasons for each revocation, are reprinted at the end of this document.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/04/20/2023-08281/revocation-of-two-authorizations-of-emergency-use-of-in-vitro-diagnostic-devices-for-detection-andor)
- API: https://www.federalregister.gov/api/v1/documents/2023-08281

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
